PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY
Conditions: Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes Interventions: Drug: Tegafur Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Esophagus Cancer | Hospitals | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Skin Cancer | Squamous Cell Carcinoma | Study